Skip to content

Advertisement

The prominent alteration in transcriptome and metabolome of Mycobacterium bovis BCG str. Tokyo 172 induced by vitamin B1

BMC Microbiology201919:104

https://doi.org/10.1186/s12866-019-1492-9

©  The Author(s). 2019

  • Received: 26 October 2018
  • Accepted: 14 May 2019
  • Published:

Abstract

Background

Vitamin B1 (VB1) is a crucial dietary nutrient and essential cofactor for several key enzymes in the regulation of cellular and metabolic processes, and more importantly in the activation of immune system. To date, the precise role of VB1 in Mycobacterium tuberculosis remains to be fully understood.

Results

In this study, the transcriptional and metabolic profiles of VB1-treated Mycobacterium. bovis BCG were analyzed by RNA-sequencing and LC-MS (Liquid chromatography coupled to mass spectrometry). The selection of BCG strain was based on its common physiological features shared with M. tuberculosis. The results of cell growth assays demonstrated that VB1 inhibited the BCG growth rate in vitro. Transcriptomic analysis revealed that the expression levels of genes related to fatty acid metabolism, cholesterol metabolism, glycolipid catabolism, DNA replication, protein translation, cell division and cell wall formation were significantly downregulated in M. bovis BCG treated with VB1. In addition, the metabolomics LC-MS data indicated that most of the amino acids and adenosine diphosphate (ADP) were decreased in M. bovis BCG strain after VB1 treatment.

Conclusions

This study provides the molecular and metabolic bases to understand the impacts of VB1 on M.bovis BCG.

Keywords

  • Transcriptomics
  • Metabolomics
  • BCG
  • Vitamin B1
  • Growth inhibition

Background

Mycobacterium tuberculosis (Mtb), causative agent for Tuberculosis, is the leading infectious cause of death worldwide. The difficulties associated with the treatment and control of tuberculosis are mainly due to the ability of Mtb to persist in a dormant state and maintain viability in the absence of cellular replication. Although the use of anti-TB drugs such as rifampicin (RIF) and isoniazid (INH) has been widely accepted, the treatment outcome may be worsened by the presence of multidrug resistant (MDR) strains of Mtb. Moreover, the appearance of MDR and XDR (extensively drug resistant) strains can reduce the treatment success in TB. Therefore, the discovery of novel anti-Tuberculosis drugs and the implementation of effective Tuberculosis prevention programme have become a major focus of Tuberculosis research.

The application of transcriptomics has been driven by bioinformatic analysis for the identification of key variable genes that upregulated and downregulated in bacterial strains under different conditions. The primary aim of this approach is to decipher how the pathogens regulate their gene expression and host transcriptional machinery. This approach will provide a better understanding of molecular events and help to identify the key genes responsible for the pathogenesis of Mtb under different exposure conditions. For instance, transcriptional studies have been applied in Mtb under nutrient starvation, acidic and oxidative stress conditions [1–3]. Moreover, transcriptional profiling have been carried out on soil bacterium M. smegmatis and Mtb following the exposure to low and high levels of hydrogen peroxide and to vitamin C (Vc), respectively [4, 5]. In vivo, macrophages with similar host environment have been used to study the host response to infection [5]. Numerous transcriptional studies have been conducted using primary cultures of human and murine macrophages [6–8].

Metabolomics has been used to describe the complete set of complicated and interrelated chemical transformations that enable individual cells to replicate and survive. Metabolite represents the final downstream outcome of genome transcription, which contains a mixture of high- and low-molecular weight compounds involved in the metabolic reactions during normal cell growth and preservation [9]. Due to the importance of metabolism, numerous studies have been focused on Mtb metabolism, including central carbon metabolism [10], cofactor metabolism [11, 12], sulfur, nitrogen and phosphorus metabolism [13, 14]. More importantly, metabolomic analysis enables us to identify the potential biomarkers for diseases. For instance, the impact of Mtb infection on host metabolism has been studied in several experimental models such as mice and guinea pigs [15, 16]. Moreover, clinical subjects with distinct metabolite profiles have been used to distinguish uninfected patients from those with active disease and latent infection.

Thiamin (Vitamin B1), in its active form thiamin diphosphate (ThDP), is an essential cofactor for all organisms [17–19]. Vitamin B1 (VB1) is involved in energy metabolism and the degradation of sugars and carbon skeleton [19]. VB1 has a multifaceted role in the regulation of gut immunity by maintaining the functions of naive B cells and utilizes the energy released from the citric acid cycle [20]. In addition, VB1 participates in the activation of immune system, nerve tissue repair, neuronal communication, brain development, brain function and cell-membrane dynamics [21–23]. Furthermore, VB1 can diminish the concentrations of reactive nitrogen species in cells as a consequence of its antioxidant activity, but has no significant effects on reactive oxygen species [24]. Despite the fact that bacteria, fungi and plants are able to synthesize VB1 de novo, mammals are entirely reliant on a dietary source of VB1. Nevertheless, VB1 deficiency may result in an increased lactic acid production and lead to metabolic and neurological disorders [25].

To date, vitamin A (VA), VC and vitamin D (VD) supplementation have been used as adjunct to anti-tuberculosis drugs [26–28]. VC is capable of inhibiting the growth of Mtb due to the reduction of ferric to ferrous ions. The ferrous ions may result in the production of reactive oxygen species (i.e. hydrogen peroxide, superoxide and hydroxyl radicals) through Harber–Weiss cycle and Fenton reactions, which give rise to pleiotropic effects associated with certain cellular processes [28], VD itself may not exert anti-TB activity; instead, its metabolite 1,25(OH)2D3 (1α,25-dihydroxyvitamin D3) can inhibit the growth of Mtb and regulate the immunity of host cells via phagosome-lysosome fusion [29]. Additionally, VB5 can reduce the growth of intracellular Mtb in macrophage in vitro, and confer protection against mycobacterial infection by enhancing the maturity of macrophages and inducing the differentiation of Th1 and Th17 cells in mice infected with Mtb [30]. Our recent study demonstrated that VB1, VC and VA can decrease the binding affinity between Rv3291c(MtbLrpA) and DNA [31]. In addition, in our data we found that VB1 with a final concentration of 10 mM can inhibit the growth of BCG in vitro. By considering the importance of VB1, VA, VC and VD, we proposed that lacking certain vitamins may play a role in bacterial persistence.

Therefore, in the present study, the transcriptomic and metabolomic analyses were conducted on M. bovis BCG after VB1 induction, by using RNA-sequencing and LC-MS platforms, respectively. The results indicated that VB1 exhibited an inhibitory effect on the growth of BCG in vitro. Candidate genes involved in the cell wall formation, energy metabolism and metabolic regulation were differentially expressed in BCG cultures in the absence and/or presence of VB1. Furthermore, the concentrations of amino acids and metabolites such as adenosine diphosphate (ADP), inosine and so on were decreased after VB1 treatment.

Results

Inhibitory effects of VB1 on BCG growth and its minimum inhibitory concentration

Previous study demonstrated that VD can suppress the intracellular growth of M. tuberculosis in vitro [32]. In addition, the high dose of VC was found to sterilize M. tuberculosis cultures in vitro [28]. In the present study, VB1 was added in certain medium at different final concentration of 1.0, 2.0, 4.0, 8.0, 10 mM, in order to test the effect of VB1 on BCG growth. It was observed that 8 mM VB1 has inhibited the growth rate of BCG (Fig. 1). In addition, the minimum inhibitory concentration (MIC) of VB1 was detected as 8 mM (data not shown).
Fig. 1
Fig. 1

Effect of VB1 on BCG growth. BCG cultures were inoculated into 7H9 liquid medium, and treated with different concentrations of VB1 (1.0, 2.0, 4.0, 8.0, 10.0 mM). BCG cultures without VB1 treatment were used as controls. The OD600nm value was detected every seven days. Each condition was tested in triplicates. X-axis represents the time (Unite is day), while Y-axis represents the log of CFU count

Genome expression analysis of BCG following VB1 treatment

A total of 100 genes (2.5% of whole genome) were induced, whereas 160 genes (4% of whole genome) were repressed for more than 2-fold (Additional file 1: Table S3). Fold changes were calculated by the power of 2 for all the studied genes. For both GO and KEGG enrichment analyses, corrected P<0.05 was selected as a threshold to determine the significant enrichment of each gene set. The genes with an adjusted P-value of ≤0.05 were identified as differential expression. GO analysis of the transcripts was identified through Bio::SAGE::Comparison tool (https://metacpan.org/pod/Bio::SAGE::Comparison). The GO enrichment transcriptional analysis revealed that the differentially expressed genes in BCG strain treated with 8 mM of VB1 were significantly enriched in the following functional categories:“cell wall”, “cytosol”, “response to host immune response”, “cellular response to nitrosative stress”, “response to hypoxia”(Fig. 2a). On the other hand, KEGG analysis of the transcripts was performed by BLAST against KEGG database. KEGG enrichment analysis indicated that most of the variable genes were associated with the following biological processes: “microbial metabolism in diverse environments”, “biosynthesis of antibiotics”, “carbon metabolism”, “two–component system”, “biosynthesis of amino acids”, “nitrogen metabolism” and “fatty acid metabolism”(Fig. 2B). The major identified functional groups are discussed below.
Fig. 2
Fig. 2

GO enrichment and KEGG pathway analysis of BCG treated with 8 mM VB1. (a) GO enrichment analysis. (b) KEGG pathway analysis. The numbers of genes in Top 30 of GO and Pathway Enrichment are listed on the left side of the figures, respectively

NarGHJI operon

The 4-gene NarGHJI operon, JTY_RS06200 (narG) to JTY_RS06215 (narI) were downregulated at different degree and NarG was repressed 2-fold in VB1 treated culture (Additional file 2: Table S7). NarGHJI operon encodes for nitrate reductase, an enzyme that reduces nitrate to nitrite during the absence of oxygen, representing the first step of ammonification and denitrification [33]. Nitrogen and nitrogen compounds play an important role in the battle between hosts and pathogens. Nitrate reductase utilizes reactive nitrogen intermediates to promote the growth of Mtb in macrophages. During this process, NarG encoding nitrate reductase may play an essential role. Interestingly, NarG is a conserved protein in mycobacteria, and can be used as an ideal taxonomic marker for sorting different species in mycobacterium [33]. Besides, NarG mutant strains have been used to infect the severe combined immunodeficient mice, which leads to less extensive tissue damage compared wild type strains, indicating that nitrate respiration contributes significantly to the virulence of M. bovis BCG [34].

Regulators

Mtb exhibits an increased pathogenicity due to its ability to adopt a dormant state, which may retain a lifelong risk of latent tuberculosis infection. The regulators play an important role in response to the surrounding environmental conditions, by changing the expression levels of the corresponding genes. In the present study, a total of 20 genes constituting approximately 10% of all BCG regulators were significantly altered in response to VB1 treatment. It is noticeable that five group of two-component transcription regulators were significantly changed in BCG cells after VB1 treatment.

The downregulation of JTY_RS10535 (Rv2034) may regulate the expression of dosR gene and plays a significant role in lipid metabolism and hypoxic adaptation [35]. In addition, Rv2034 is one of the in vivo expressed Mtb antigens (IVE-TB), which is considered as the potential TB vaccine candidate antigen. This observation is based on the expression of Rv2034 during the process of inflammatory pulmonary infection and the specificity of cloned T cells for Rv2034 to inhibit Mtb outgrowth from infected monocytes [36, 37]. The downregulated JTY_RS18665 (Rv3574) is a member of TetR family transcriptional regulators, which is highly conserved in the mycobacteria. This multiple stress responsive transcriptional regulator controls a number of regulons that participate in the lipid degradation and induces the corresponding genes associated with lipid metabolism. Moreover, JTY_RS18665 (Rv3574) positively regulates KstR and potentially acts as the main regulator of lipid metabolism during hypoxia-induced dormancy [38, 39].

In the Mtb transcriptional regulatory network, JTY_RS00450 (Rv0081) represents an essential regulatory hub and modulates the response to hypoxia in the long-term survival of M. tuberculosis [40]. Previous study has reported that the incubation of this protein with whole blood isolated from latently infected individuals may stimulate the activation of IFN-γ, suggesting the antigenic properties of this protein [41]. In VB1-treated culture, JTY_RS00450 (Rv0081) was downregulated by 13-fold (Additional file 2: Table S2).

DosR, a crucial regulator, belongs to two component regulatory system, which enhances dormancy adaptation of M. tuberculosis under low oxygen conditions and is responsible for latent tuberculosis infection. Upon exposure to hypoxia, nitric oxide, carbon monoxide, or ascorbic acid, DosR induces the expression of 48 genes that are referred as DosR regulon, including dosRS, hspX, narK2, tgs1 and so on [42–46]. However, only a few of these regulon have been functionally characterized, while most of them are of unknown function [47]. A recent study has demonstrated the role of DosR regulon in metabolic adaptation, which is important for Mtb to shift from an actively respiring to dormancy [48]. Hence, the function of DosR regulon is indispensable for bacterial survival during the dormant state and JTY_RS16225 (Rv3133c) was repressed by 5-fold in VB1-treated culture in this study (Additional file 2: Table S2).

When M. tuberculosis is in its dormant state, this pathogen can persist in a hostile environment through many different ways. One of these is the rapid downregulation of ribosome biogenesis to match the decreased translational demand, which requires the coordinate transcriptional regulation of the synthesis of all ribosome elements. CarD is an essential protein that modulates the mycobacterial rRNA transcription. Loss of CarD has been reported to be lethal for mycobacteria in vitro and during infection of mice. Moreover, CarD depletion may increase the susceptibility of M. tuberculosis to being killed by starvation, oxidative stress and DNA damage, accompanied by failure to reduce rRNA transcription [49]. In this study, JTY_RS18710 (Rv3583c) was decreased more than 2-fold in VB1 supplemented culture (Additional file 2: Table S2).

The metabolic regulator JTY_RS17900 (WhiB3) was up-regulated more than 2.4-fold in VB1-treated mycobacterial cells (Additional file 2: Table S2). WhiB3 includes the 4Fe-4S (iron-sulfur) cluster proteins and serves as a redox sensor and effector molecule, which regulates the redox homeostasis and virulence via interaction with specific host gases (e.g. O2 and NO) [50]. The expression of WhiB3 is drastically increased upon acid stress, while weakly induced upon exposure to oxidants during the growth of Mtb under different environmental pressure conditions [51]. In VC and H2O2-treated mycobacterial cells, the expression of WhiB3 is induced more than 2-fold. Thus, both VC and peroxide can stimulate the expression of the corresponding protein [4, 52, 53].

Under nitric oxide treatment and macrophage infection, the expression level of transcription regulator JTY_RS20155 (WhiB6) is highly upregulated [54]. WhiB6 is able to regulate the expression of ESX-1 during mycobacterial dissemination and granuloma formation in zebrafish embryo model [55]. Through comparative transcriptomic analysis, WhiB6 has been shown to regulate aerobic and anaerobic metabolism, virulence and cell division [54]. In VB1-treated cells, JTY_RS20155 (Rv3862c) was upregulated more than 3-fold (Additional file 2: Table S2).

The repressor JTY_RS20120 (Rv3855) belonging to TetR/CamR family transcriptional regulators was upregulated by approximately 2-fold in VB1-treated culture (Additional file 2: Table S2). In Mycobacterium genome, Rv3854c (ethA) and Rv3855 (ethR) can confer to the resistance to antitubercular drug ethionamide (ETH) among patients infected with MDR strains of M. tuberculosis. In addition, the ethA-ethR-deficient M. bovis BCG mutant displays an increased adherence to mammalian cells and enhanced persistence in vivo [56].

Rv3066 is one of TetR family regulator and represses the transcription of mmr by directly binding to the inverted repeat (IR) of promoter [57], Mmr (Rv3065) is a multidrug efflux pump, which belongs to the SMR (small multidrug resistance) family. Mmr can modulate the resistance to some toxic compounds, including ethidium bromide, acriflavine, safranin O, pyronin Y, tetraphenylphosphonium and thioridazine [58, 59]. Furthermore, Mmr is able to recognize and eliminate a large range of antimicrobial agents, thus leading to the intrinsic resistance to antimicrobials in Mtb. The results of transcriptomics analysis demonstrated that JTY_RS15890 (Rv3066) was upregulated by 2-fold in VB1-treated cells (Additional file 2: Table S2).

DNA replication, translation and repair

The M. tuberculosis genome encodes an NAD+-dependent DNA ligase (ligA) and three diverse ATP-dependent ligase homologs, namely, ligB, ligC, and ligD [60]. Two of them are repressed in VB1-treated BCG cultured cells, suggesting that the reduced growth rate of BCG was possibly due to the retardation of replication process.

The detected genes were also involved in the process of translation, such as those encoded by 50S ribosomal proteins (i.e. rpmB1, rplE, rplD, rplC, rplW and rplB) were downregulated, leading to a decrease in the demand for mRNA and protein synthesis during the state of dormancy. In addition, JTY_RS00440 (Rv0079), a member of DosR regulon, is involved in the regulation of translation initiation via the interaction between bacterial ribosomal subunits and its products in order to inhibit the protein synthesis and bacteria growth [61–63]. It was observed that the expression level of Rv0079 was 6-fold lower after VB1 treatment (Additional file 2: Table S2).

In addition, high-level expression of chaperone proteins under various stress conditions may prevent the irreversible loss of protein function [64]. GroEL is believed to function as chaperonin cage, which can alter the rate of protein folding [65]. Although the mechanism underlying GroELs-facilitated protein folding is not clearly understood, it has been observed that these GroELs do not demand ATP to promote protein folding [66]. In this study, JTY_RS02300 (Rv0440) that encodes molecular chaperone GroEL was identified to be upregulated 2-fold in VB1-treated samples (Additional file 2: Table S2).

Response to DNA damage is crucial for bacterial survival. The JTY_RS14065 (Rv2720) LexA is a key element of SOS regulatory network involved in the bacterial response to DNA damage, which is commonly found among bacteria and displayed a substantial discrepancy in transcriptional regulation [67]. In VB1-treated BCG culture, the expression level of lexA was decreased, suggesting that the activation of DNA repair system in BCG is essential for dormancy survival.

Energy metabolism (fatty acid/cholesterol/glycolipid)

Acquisition and utilization of nutrients within the host cells is one of the main factors contributing to the long-term persistence of Mtb. Certain lipid precursors, such as cholesterol are required for the host cells, which can promote the survival of Mtb and its infection [68]. The results of transcriptomic analysis indicated that the majority of the genes related to cholesterol metabolism were downregulated in VB1-treated BCG culture. For example, JTY_RS18520 (fadA5) encoding for acetyl-CoA-acetyltransferase is involved in the catabolism of cholesterol, which provides a carbon source for energy production. In the infectious mouse model, the fadA5 mutant showed an attenuated disease phenotype as compared to the wild-type strain during chronic infection. Therefore, fadA5 is considered crucial to the survival of Mtb in vivo, and can be used as a potential drug target [69]. Additionally, JTY_RS18515 (cyp125), a cholesterol hydroxylase gene, is encoding cytochrome-P450-steroid-C27-monooxygenase, which involved in the cholesterol catabolism of M. bovis BCG, Mtb and other strains [70].

JTY_RS18475 (kstD) encodes 3-oxosteroid-1-dehydrogenase that regulates cholesterol through 4-androstene-3,17-dione/1,4-androstadiene-3,17-dione (AD/ADD) pathway. Deletion of kstD gene may suppress Mtb growth due to the inactivation of cholesterol degradation pathway.

JTY_RS16210 (tg1) encodes diacylglycerol-O-acyltransferase enzyme and is potentially encoding triacylglycerol synthase (TGS). Triacylglycerol (TG) is widely used as an energy source for the intracellular growth of pathogen. It is reported that the accumulation of TG is essential for the metabolism of Mtb [71]. In this study, the expression levels of Rv3130c (tg1) were downregulated 14-fold in BCG culture following VB1 treatment (Additional file 2: Table S2).

Nitrogen and nitrogen compounds play an important role in the battle between M.tuberculosis and host cells. M.tuberculosis can utilize nitrate as a final electron acceptor under anaerobic conditions to enhance its survival. Certain genes involved in nitrogen assimilation such as JTY_RS01345 (Rv0253), JTY_RS06200 (Rv1161) and JTY_RS01340 (Rv0252) were repressed more than 2-fold in VB1-treated cells (Additional file 2: Table S2). Besides, the expression levels of operon NarGHJI encoding nitrate reductase were also decreased.

Through metabolic adaptation, M. tuberculosis encounters a range of different microenvironments in its host. Glucose is one of the most abundant and essential carbon sources for many pathogenic bacteria such as M. tuberculosis. In M. tuberculosis, glycolytic pathway is highly conserved and fructose-6-phosphate phosphorylation is the key step in glycolysis process catalyzed by phosphofructokinase (PFK) activity. The genomic analysis predicted that there are two genes, namely, pfkA (rv3010c) and pfkB (rv2029c), encoded for putative PFK. Recent studies demonstrated that PFKA of Mtb accounted for the overall PFK activity without functional redundancy of PFKB. Notably, the minor isoenzyme PFKB of E. coli is responsible for around 10% of PFK activity. It is thus possible that Mtb PFKB possesses the ability to phosphorylate sugar-based substrates in addition to fructose-6-phosphate [72]. In VB1 treated culture, JTY_RS10510 (rv2029c) was downregulated by approximately 50-fold (Additional file 2: Table S2).

In overall, the majority of these genes are participated in energy metabolism, including the fatty acid, cholesterol and glycolipid metabolism. It is postulated that pathogens downregulated its metabolic activity to reduce energy consumption and to persist in a prolonged dormant state.

Ion-related protein

The balance of metal ions (e.g. iron, copper, zinc and magnesium) concentrations in the host cell is crucial for the adaptation to the environmental changes during the host responses to pathogen invasion. Bacterial growth is involved in a series of biological actions in terms of storage, transport and the use of metal ions. Recently, copper has been proposed to be used directly as a host defense mechanism, since a high concentration of copper was found in the mycobacterial phagosome [73]. The elevated copper levels are toxic and harmful to the cells through the induction of oxidative stress via Fenton reactions [74]. In addition, high copper levels can induce Fe-S clusters destabilization [75] and replace metal cofactors in proteins. Nevertheless, copper has been shown to act as a metalloenzyme cofactor and is mainly involved in controlling all types of cellular activities [76].

JTY_RS05125 (csoR) is an essential gene that is necessary for the retention of copper homeostasis in Mtb, while the target deletion of csoR is able to promote survival of Mtb during the early stages of chronic infection [77]. However, csoR has been shown to repress the expression of cso operon in the absence of copper [78]. In the present study, cso operon (csoR-Rv0968-ctpV-Rv0970) was up-regulated by approximately 2-fold in VB1-treated BCG cultured cells (Additional file 2: Table S2). Moreover, ctpV (JTY_RS05135) potentially functions as a copper exporter and is essential for copper detoxification in Mtb. In animal models, ctpV deletion mutant exerts a potent strong effect on host immune response in Mtb [79]. Overall, these findings suggest that M. bovis BCG is able to adapt to VB1 treatment conditions, by regulating the copper concentrations, control the exports of copper and retain a safe intracellular environment for Mtb to maintain its dormant phase.

Transport

ABC transporters are crucial for survival of Mtb, with regard to nutrients uptake and toxicants efflux. In Mtb genome, approximately 2.5% genes encode the ABC transporter proteins, including peptide transporters, macrolide transporters, amino acid transporters, carbohydrate transporters, iron transporters, anion transporters and so on [80]. In particular, there are two peptide permease operons dpp (rv366c-rv3663c) and opp (rv1283c-rv1280c) in the genomic sequence of M. tuberculosis H37Rv [81]. Both contain two nucleotide-binding subunits and integral membrane proteins, and one substrate-binding polypeptide [82]. The rv3665c-rv3662c encodes for the oligopeptide transporter of M. tuberculosis, basing on the fact that an rv3665c-rv3662c knockout mutant is resistant to bialaphos [83]. Microarray expression profiling has clearly indicated that the rv3665c-rv3663c locus regulates at least some genes which are induced during nutrient deprivation and hypoxia [81]. In the present study, our expression results indicated that dppA-dppB-dppC-dppD (Rv3666c-Rv3665c-Rv3664c-Rv3663c) genes were all downregulated.

Mtb UspABC transporter, one of four Mtb ABC transporters, has been shown to be essential for the growth of M. tuberculosis in vitro [84]. UspABC transporter may have a key function in the assimilation of amino sugars that enables Mtb to optimize the use of limiting nutrients during intracellular infection [85]. This observation supports the possible role of UspABC transporter in the recycling ingredient of cell-wall peptidoglycan [85]. Furthermore, our data demonstrated that the expression levels of uspABC operon were downregulated more than 2-fold in BCG culture supplemented with VB1 (Additional file 2: Table S2).

Cell wall formation

The cell walls of Mtb have a high lipid content, which are composed predominantly of mycolic acids. Cell walls may play an important role in Mtb pathogenesis through the control of its own cellular processes, including neutralization of free radicals, alterations in membrane permeability and modulation of host immune response [86]. Mycolic acids are able to increase host survival rates and reverse antibiotic resistance, due to low permeability of cell walls. Therefore, identification of the major enzymes involved in mycolic acid biosynthesis may lead to the development of novel drug targets for TB treatment. In Mtb, there are six accD genes encoding for acyl-CoA carboxylases. Notably, JTY_RS05160 (rv0974c) or known as accD2, is believed to take part in mycolic aicd biosynthesis. Cell wall-bound mycolic acids were absent in accD2 and accD3 mutants, suggesting that these mutants are indeed deficient for mycolic acid synthesis [87]. The transcriptomic analysis demonstrated that rv0974c was almost 4-fold lower when treated with VB1 (Additional file 2: Table S2).

JTY_RS10525 (Rv2032c) or acg gene, encoding the NAD(P) H nitroreductase, was downregulated about 30-fold in VB1 treated BCG culture (Additional file 2: Table S2). Deletion of acg produced a mutant that is attenuated in both macrophage and murine model infections. However, acg deletion did not come to terms with the viability of the mutant in vitro and in vivo, under oxidative and nitrosative stresses. Moreover, the acg mutants are more sensitive to antibiotic drugs (e.g. nitrofurantoin and nitrofuran) than the WT strain. Thereby, acg is a key virulence factor for Mtb, which enhances the growth and survival of Mtb in macrophages and mice [88].

PE and PPE families proteins

PE and PPE are glycine-rich proteins that constitute approximately 10% of Mtb proteome. However, the function of these glycine-rich proteins is unknown [89]. Recent studies have proposed that these two protein families may contribute to the bacterial persistence in granulomas, the bacterial survival in macrophages and the antigenic change [90, 91]. During the infection process, phagocytes can kill intracellular microorganisms via the inhibition of phagosome acidification. Further, this prevents the fusion between lysosome and phagosome [92]. It has been reported that a strain lacking JTY_RS09290 (Rv1787) is attenuated in vivo and does not inhibit the phagosome-lysosome fusion and the acidification of vacuole, suggesting that this protein may be involved in the development of bacterial intracellular environment and the formation of phagosome [93]. In VB1-treated culture, the expression levels of Rv1787 were upregulated by approximately 2-fold (Additional file 2: Table S2).

In addition, it has been reported that JTY_RS17945 (Rv3425) is encoded by an open reading frame located in the RD11 region of Mtb genome and this protein is expressed during the exponential growth in vitro [94]. Rv3425 exhibited both IgG1 antibody response and Th1/Th2 immune response following immunization in mice, supporting that this protein is involved in the production of a potent cellular and humoral immune response. Moreover, vaccines containing Ag85B and Rv3425 antigens promote the effects of immunity and confer a protection against Mtb infection in C57BL/6 mice [95]. Therefore, Rv3425 may be a promising vaccine candidate for TB treatment. In the present study, VB1 treatment induced a 3-fold increase in Rv3425 expression levels in BCG culture as compared to the control sample (Additional file 2: Table S2).

JTY_RS10910 (Rv2108) can be used for the rapid detection and identification of mycobacteria complex containing M. africanum, M. bovis and M. bovis BCG strain, due to its high specificity towards Mtb complex [96]. In a previous study, the recombinant p27-PPE36 (Rv2108) protein is immunologically active and reacts with antibodies in the sera of TB patients, as detected by ELISA assay [97]. It is worthwhile to note that the presence of IgA and absence of IgG antibody responses can be used as the specific diagnosis markers for Mtb [98]. The current transcriptomic data indicated that the expression levels of PPE36 were upregulated more than 3-fold in VB1-treated cells (Additional file 2: Table S2).

Hypothetical protein

The transcriptomic analysis indicated that the expression levels of the 260 genes were altered in the bacterial cells following VB1 treatment. Among these genes, 51 (19%) were encoded for hypothetical proteins. The functions of several hypothetical proteins have been reported, but most of them are of unknown function. For example, the conserved hypothetical genes JTY_RS09425 (Rv1813c) and the co-transcribed JTY_RS09420 (Rv1812c) are encoded for dehydrogenase. Rv1813c is predicted to be related with Mtb virulence in vivo [99]. In this study, both genes were downregulated at a factor of higher than 9-fold and 2-fold, respectively. Moreover, JTY_RS10515 (Rv2030c), JTY_RS16955 (Rv3269), JTY_RS00440 (Rv0079c), JTY_RS09435 (Rv1815) and JTY_RS13660 (Rv2627c) were downregulated more than 3-fold. In contrast to those genes, JTY_RS12370 (Rv2390c), JTY_RS00960 (Rv0179c), JTY_RS08085 (Rv1535), JTY_RS13125 (Rv2525c) and JTY_RS09350 (Rv1799) were upregulated more than 2-fold (Additional file 2: Table S2).

Universal stress protein

There are 10 universal stress proteins (ups) in M. tuberculosis, most of the function are unknown. Recently, proteomic and transcriptomic analyses have revealed that a number of usp genes are significantly upregulated under nitric oxide, carbon monoxide and hypoxia conditions, as well as during M. tuberculosis infection of macrophage cell lines [100]. It is worth to mention that the expression levels of 10 universal stress proteins such as JTY_RS10505 (Rv2028c), JTY_RS16230 (Rv3134c), JTY_RS13645 (Rv2624c), JTY_RS13640 (Rv2623c), JTY_RS10325 (Rv1996), JTY_RS10375 (Rv2005c), JTY_RS12040 (Rv2319c), JTY_RS08515 (Rv1636c), JTY_RS10495 (Rv2026c) and JTY_RS05465 (Rv1028c) were repressed at different magnitudes. Among these stress proteins, Rv2028c, Rv1996 and Rv2005c that belong to M. tuberculosis DosR regulon were repressed at 36, 7 and 2 folds, respectively, among the VB1-treated BCG culture (Additional file 2: Table S2).

RT-qPCR verification for the expression of selected genes

A total of 20 genes were selected for qRT-PCR examination in order to confirm the obtained transcriptomic data (Fig. 3). The primers used in the qRT-PCR assay are listed as the supplementary materials (Additional file 3: Table S1). The alteration in the levels of expression corresponded to the results of sequencing.
Fig. 3
Fig. 3

The relative expression of selected genes. The relative expression levels of selected genes in the presence and absence of 8 mM VB1 by qRT-PCR analysis. Standard deviations (calculated for three biological replicates) are indicated. X-axis represents the identities of tested genes; Y-axis represents the fold-changes of tested genes in both VB1 treatment and control groups. a The fold-changes of upregulated genes following VB1 treatment. The genes listed on the X-axis are JTY_RS00695 (Rv0129c), JTY_RS01000 (Rv0186A), JTY_RS02300 (Rv0440), JTY_RS05235 (Rv0986), JTY_RS07460 (Rv1405c), JTY_RS10910 (Rv2108), JTY_RS12600 (Rv2428), JTY_RS15805 (Rv3049c), JTY_RS18025 (Rv3445c) and JTY_RS20155 (Rv3862c). b The fold-changes of downregulated genes following VB1 treatment. The genes listed on the X-axis are JTY_RS00455 (Rv0082), JTY_RS05530 (Rv1039c), JTY_RS10385 (Rv2007c), JTY_RS10510 (Rv2029c), JTY_RS10520 (Rv2031c), JTY_RS16215 (Rv3131), JTY_RS16220 (Rv3132c), JTY_RS16225 (Rv3133c), JTY_RS16230 (Rv3134c) and JTY_RS20045 (Rv3841)

As illustrated in Fig. 3, the genes JTY_RS10385 (Rv2007c), JTY_RS10520 (Rv2031c), JTY_RS16215 (Rv3131), JTY_RS16230 (Rv3134c), JTY_RS16225 (Rv3133c), JTY_RS05530 (Rv1039c), JTY_RS20045 (Rv3841), JTY_RS16220 (Rv3132c), JTY_RS00455 (Rv0082), JTY_RS10510 (Rv2029c) encoding ferredoxin, alpha-crystallin, NAD(P) H nitroreductase, universal stress protein, transcriptional regulator, PPE family protein, ferritin BfrB, histidine kinase, oxidoreductase and phosphofructokinase were downregulated at 32, 46, 13, 11, 15, 4, 6, 7, 21, 9 folds, respectively. On the contrary, the genes JTY_RS12600 (Rv2428), JTY_RS07460 (Rv1405c), JTY_RS15805 (Rv3049c), JTY_RS20155 (Rv3862c), JTY_RS02300 (Rv0440), JTY_RS10910 (Rv2108), JTY_RS01000 (Rv0186A), JTY_RS05235 (Rv0986), JTY_RS18025 (Rv3445c), JTY_RS00695 (Rv0129c) encoding alkyl hydroperoxide reductase subunit C, methyltransferase, NAD(P)/FAD-dependent oxidoreductase, transcriptional regulator, molecular chaperone GroEL, PPE family protein, metallothionein, ABC transporter ATP-binding protein, ESAT-6 like protein EsxU and diacylglycerol acyltransferase were upregulated at 25, 13, 7, 6, 11, 4, 9, 5, 6 and 3 folds, respectively (Fig. 3).

LC-MS analysis of amino acids and metabolites

By considering that most of the amino acid metabolic pathways were altered, we aimed to investigate the effects of individual amino acid levels in the VB1-treated and wild strain BCG cultures. The results of LC-MS demonstrated that the concentrations of most amino acids, except for methionine, were higher than 1.0-fold in the VB1-treated group as compared to the untreated group (Additional file 4: Table S4).

In addition to amino acids, the metabolites were also detected by LC-MS. Each condition has 6 samples except for 1 sample in control group was ommited because the problem of samples. The heatmap analysis was shown in Fig. 4. Of these, four metabolites, namely, 5-S-methyl-5-thioadenosine, PE (18:1(9Z)/0:0), S-adenosylhomocysteine and LysoPE (0:0/18:2(9Z,12Z)) were upregulated at least 2-fold, whereas the remaining metabolites including L-tryptophan, inosine, geranylgeranyl PP, adenosine 5-phosphate disodium, 4-nonylphenol and ADP were downregulated by 2-fold (Additional file 5: Table S5).
Fig. 4
Fig. 4

The heatmap analysis of different metabolites in VB1 treatment and control groups. The red and blue colors indicate metabolites with increased and decreased levels, respectively. The rows represent control samples (CK-1, CK-2, CK-3, CK-4 and CK-5) and experimental samples treated with VB1 (VB1–1, VB1–2, VB1–3, VB1–4, VB1–5 and VB1–6). The identities of metabolites are listed on the right side of the heatmap

The associated KEGG pathway for both transcriptomics and metabolomics data

For the analysis of both transcriptomics and metabolomics data, we explored the KEGG pathway involved in the primary and secondary metabolism of M. bovis BCG after VB1 induction. Differentially expressed genes and metabolites mainly participated in 9 KEGG pathways, including nitrogen metabolism, purine metabolism, methane metabolism, cysteine and methionine metabolism, secondary metabolites biosynthesis, terpenoid backbone biosynthesis, oxidative phosphorylation, photosynthesis and metabolic pathways. The metabolite compounds such as S-adenosylhomocysteine, geranylgeranyl PP, inosine and ADP fluctuated in BCG culture after treated with VB1. Moreover, the number of expressed genes involved in metabolic pathways, biosynthesis of secondary metabolites, nitrogen metabolism, purine metabolism, methane metabolism, oxidative phosphorylation and terpenoid backbone biosynthesis were 572, 295, 21, 60, 24, 43 and 27, respectively. All the corresponding genes were downregulated, and the concentrations of ADP, inosine and geranylgeranyl PP were also decreased (Additional file 6: Table S6).

Nitrogen is a basic biomolecule for amino acids, nucleotides, cell wall components and cofactors. Nitrogen metabolism plays an essential role in the life cycle of M. tuberculosis. In this study, the 21 genes participating in nitrogen metabolism were downregulated and the concentration of ADP was decreased in VB1-treated culture.

Despite their fundamental importance in forming the building blocks for DNA and RNA, purine metabolites may supply the cells with energy and cofactors to promote cell survival and multiplication [101]. The 60 genes involving in purine metabolism were downregulated at different magnitudes in the VB1-treated culture. Similarly, the concentrations of ADP and inosine metabolites were reduced.

Discussion

Vitamin B consists of eight well-recognized members with high water solubility, which is involved in various metabolic pathways and host immunization. VB1 is a pivotal cofactor for all living microorganisms and exerts a significant function in the activation of immunization. The administration of VB1 as a dietary supplement can reduce the incidence of many types of cancer [102]. In addition, VB1 can be used to treat Parkinson’s disease via multiple mechanisms of action, including oxidative stress, inflammation, protein expression and cellular metabolism. The therapeutic applications of VB1 have extended to the prevention of immune HIV-associated complications. VB1 exerts beneficial effects in HIV patients through the protein expression of vascular endothelial growth factor and matrix metalloproteinase [103, 104]. In the present study, the physiological outcome of VB1 treatment in M. bovis BCG was examined by both transcriptomic and metabolomic analyses. The findings indicated that VB1 treatment could alter various cellular processes involved in the bacterial cell growth. Firstly, VB1 reduces lipid degradation and results in low energy supply, via the downregulation of genes involved in energy metabolism. Secondly, the genes related to cell wall formation, cell division and replication were downregulated, supporting that VB1 treatment reduces the growth of BCG. Thirdly, the expression levels of the genes encoding ribosomal synthesis were decreased in BCG cells treated with VB1. These results demonstrated that VB1 treatment may influence the protein synthesis apparatus and reduce protein synthesis, leading to slow bacterial growth. Furthermore, the expression of regulators modulating various cellular processes (e.g. lipid metabolism, lipid degradation, transport and stress response) were altered in BCG culture following VB1 treatment. These data suggests that bacteria can adapt to environmental stimuli via many different regulators by using distinct mechanisms of growth inhibition. Lastly, it is important to note that NarGHJI operon were repressed in BCG treated with VB1, indicating that the process of nitrogen assimilation considerably slows down as a consequence of reduced energy sources.

LC-MS based metabolomic analysis revealed that the concentrations of amino acids (AA), except for methionine, were lower in the VB1-treated culture than in the untreated culture. In fact, AA are used to support the physiological functions of pathogen, and the variation in AA availability significantly affects the expression of virulence factor and the growth of pathogen [105]. For instance, aspartate is a primary nitrogen source that enhances the virulence of M. tuberculosis during colonization of its host [106, 107]. Asparagine is another important nitrogen source for pathogen, which can be captured and digested by AnsP2 and AnsA. Digestion of asparagine may cause pathogens to resist the host immune defense and improve their survival rates in the host [108]. Moreover, alanine can be broken down to pyruvate and ammonium by alanine dehydrogenase, and has been used as an unique nitrogen source for the growth of M. tuberculosis, M. avium and M. smegmatis [109]. Both alanine and serine can prevent the growth of BCG strains in vitro by inhibiting glutamine synthetase activity. This enzyme plays an important role in bacterial nitrogen metabolism, metabolizing nitrogen through aminate glutamate in an ATP-dependent reaction [110]. Furthermore, when glycine, asparagine and aspartate are used as the nitrogen source, M. bovis BCG can grow rapidly in Sauton medium [111]. More importantly, AA acts as the basic substrate for the synthesis of protein and other regulatory molecules such as nitric oxide, polyamines, and creatin. Besides, AA can regulate MAPK signaling pathways in controlling energy metabolism [112]. Recent studies have shown that AA plays an important role in the coordination of host innate immunity. For example, leucine and glutaminere are crucial in mediating T cell functions, including the activation and differentiation of Th1 and Th17 cells [113–115].

The combination of transcriptomics and metabolomics data indicated that a large number of annotated genes (n = 572) were involved in metabolic pathways, and the corresponding metabolites were identified as ADP, S-adenosylhomocysteine, inosine and geranylgeranyl PP. Next, a total of 295 genes were associated with secondary metabolite biosynthetic pathways, linking to the reduced metabolite levels of ADP and geranylgeranyl PP. Despite the aforementioned pathways, the genes and metabolites involved in nitrogen and purine metabolisms were downregulated. Notably, ATP which is essential for energy production and cofactors function was found to be downregulated by approximately 3.5-fold. Besides, purine and pyrimidine nucleotides are used to create the DNA and RNA. Purine nucleotides such as ATP is vital for cellular energy supply, while guanosine triphosphate (GTP) and cyclic AMP (cAMP) are the essential signaling molecules [116]. Additionally, purines can be integrated into more complex biomolecules and act as cofactors such as nicotinamide adenine dinucleotide (NAD) and coenzyme A [101]. In this study, inosine was downregulated at least 2-fold in VB1-treated BCG culture. Inosine is made up of deaminizing adenosine and can be released extracellularly under inflammatory conditions [117, 118]. Inosine has been reported to exert nutritional and neuroprotective functions in nerve cells, and stimulates mast cell degranulation by activating adenosine A3 receptor [119]. Moreover, inosine exhibits anti-inflammatory activity by inhibiting the release of inflammatory cytokine from activated T cells and promoting the formation of IL-10. Clinical trials have proposed that inosine may be a promising drug target for patients suffering from multiple sclerosis [120].

All in all, the changement of metabolites following VB1 induction suggests a downregulation of gene expression and metabolic pathways in energy metabolism. In addition, abnormal expression of nitrogen metabolism genes and lower concentration of ADP could possibly lead to the slower growth rate of BCG after being treated with VB1.

Conclusions

Overall, the findings of this study revealed that VB1 treatment can inhibit the growth of M. bovis BCG, by modulating the cellular processes such as replication, transcription, translation, transport and energy metabolism. More importantly, the expression levels of certain antigens were altered in BCG cells following VB1 treatment. These results suggest that VB1 can affect BCG growth by targeting its cellular processes and confer a protection against Tuberculosis by promoting host immunity and stimulating antigen production. Furthermore, metabolomic analysis indicated that most of the amino acid biosynthetic pathways were altered. To the best of our knowledge, the present study is the first to investigate the effects of VB1 M. bovis BCG, and provides the molecular and metabolic bases to further understand the impacts of VB1 on M.bovis BCG.

Methods

Strains, culture conditions and MIC (minimum inhibitory concentration) of VB1

Mycobacterium bovis BCG str. Tokyo 172 strain was grown in Middlebrook 7H9 medium Becton Dickinson supplemented with 0.05% Tween-80 (V/V), 10% ADC (Albumin-Dextrose-Catalase, BD) and 0.2% (V/V) glycerol. When OD600nm value reached exponential phase, VB1 with final concentration of 1.0, 2.0, 4.0, 8.0, 10 mM were added and incubated at 37 °C for 4 weeks under continuous shaking (100 rpm). At days 7, 14, 21 and 28, 100 μL of fresh BCG was spread on the appropriate plates, and then incubated at 37 °C for 4 weeks. After incubation, the number of colonies was count to determine the effect of VB1 on BCG growth. The experiments were performed in triplicate. For transcriptomics and LC-MS analysis, when OD600nm value reached 0.3, VB1 at the final concentration of 8.0 mM for the test group were added and incubated at 37 °C for 48 h. There are 3 and 6 biological samples respectively in transcriptomics and LC-MS experiments. The procedure of MIC determination is as following: BCG was cultured at 37 °C for about 10 to 15 days until an optical density (OD) of an 0.5 McFarland standard (1 × 107 CFU/mL) reached. Then the suspension was diluted 100 fold to obtain a standard inoculum with 105 CFU/mL. 100 μL of standard inoculum was inoculated onto 7H10 plates containing VB1 with final concentration of 0, 0.125, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 10.0 mM at 37 °C for 21 days. Then the colony number were counted and the MIC value was confirmed.

RNA extraction and purification

M. bovis BCG was cultured with 7H9 liquid medium in the presence and/or absence of 8 mM VB1. At time point (48 h), bacterial cells (control and VB1-treated) were collected and centrifuged. RNA isolation was carried out as described previously [31]. In brief, BCG pellets were lysed and homogenized by high-speed agitation in a bead mill with the presence of glass beads and lysis buffer to lyse the cells and release the RNA. Then total RNA was extracted using RNeasy Mini Kit (Qiagen) following the instructions provided by the manufacturer with one on-column DNase I treatment (Qiagen) at 37 °C for 30 min in order to remove any contaminating genomic DNA. DNase I was removed with RNeasy mini kit according to the clean-up procedure. All samples were analyzed by using polymerase chain reaction (PCR) with primers SN80f and SN80r (Additional file 3: Table S3), in order to confirm the absence of genomic DNA contamination. The purity of RNA samples was evaluated based on RIN value by using Agilent Bioanalyzer 2100 (Agilent technologies, Santa Clara, CA, US). The concentration of RNA samples was determined by NanoDrop ND-2000. The RNA samples with optimal quantity and purity were selected for next generation RNA-sequencing after cDNA synthesis.

Library construction and data analysis

The strand-specific library was constructed using TruSeq® Stranded Total RNA Sample Preparation kit (Illumina, USA). The ribosomal RNA was removed and the RNA fragments were cleaved, while the first and second strand cDNA were synthesized. A single ‘A’ nucleotide was added to the 3′ ends of the blunt DNA fragments with repaired ends, and subsequently connected with adapters. The purified libraries were quantified using Qubit® 2.0 Fluorometer (Life Technologies, USA) and validated by Agilent 2100 bioanalyzer (Agilent Technologies, USA), in order to measure the concentration and confirm the insert size. The cluster was generated by cBot and RNA sequencing was performed using a 150 bp pair-end strategy with the Illumina Hiseq X10 platform (Illumina, USA) to generate 3 billion bases per sample. Thereafter, raw data was acquired, followed by pretreatment using Septk1. The read length was > 90 nt. The number of average clean reads, clean reads ratio and mapping ratio for WT and VB1-treated samples were 3.3G, 97.1 and 99.6%, and 3.2G, 97.14 and 99.4%, respectively. We deposited the raw data to GEO repository under accession number GSE114949.

The raw sequencing data were filtered to remove rRNA reads, sequencing adapters, short-fragment reads and other low-quality reads. The cleaned paired-end reads were mapped to M.bovis BCG reference genome with accession number AP010918 by using Tophat v2.0.9 with two mismatches [121]. After the completion of genome mapping, Cufflinks v2.1.1 [122] was run with a reference annotation, in order to generate FPKM (Fragments Per Kilobase of exon model per Million mapped reads) values for known gene models. Cuffdiff analysis was performed to identify the differentially expressed transcripts and genes [118]. False discovery rate (FDR) was used to determine the threshold of P-value in multiple tests, on the basis of FDR ≤0.05 and fold-change ≥2 [123, 124]. Furthermore, the homology of genes in M. bovis BCG was compared with M. tuberculosis H37Rv genome, by using BLAST analysis (https://blast.ncbi.nlm.nih.gov/Blast.cgi; Additional file 7: Table S2).

cDNA synthesis and qRT-PCR

cDNA was synthesized using SuperScript III First-Strand Synthesis kit according to the manufacturer’s instructions. Quantitative real-time PCR (qRT-PCR) was performed with iQ™ SYBR Green Supermix (Bio-Rad) by using the LightCycler 480 II (Roche) RT-PCR System. The PCR conditions were as follows: initial denaturation at 95 °C for 3 min, followed by 40 cycles of denaturation at 95 °C for 10 s, annealing at 55 °C for 30 s and extension at 72 °C for 10 s. After completion of the 40th cycle, a final cycle of 50 °C was conducted for 3 min. The reactions were carried out with 50-fold diluted cDNA and 12.5 μL SYBR Green supermix. All reactions were carried out in triplicate, including the cDNA-free template and RT-free control. The Rv2703 gene encoding RNA polymerase sigma A factor (sigA) was selected as a housekeeping gene for normalization of target gene expression levels. PCR reaction efficiency was calculated by evaluating the slope of a standard curve. The curve was created by linear regression of the resulting Cq values, with a 10-fold serial dilution of DNA. The 2△△Cq method was used to calculate the relative expression levels of target genes.

LC-MS based metabolomic analysis

The BCG strains cultured with 7H9 medium in the absence and/or presence of VB1 were collected after 48 h incubation at 37 °C. In the collected 60 mg pellets, added 500 μL of methanol (pre-cooled at − 20 °C) and 500 μL deionized water (ddH2O) (4 °C) and vortex for 30 s, then added 100 mg glass beads. Placed the tubes into liquid nitrogen for 5 min and thawed at roomtemperature, then put tubes in the high flux organization grinding apparatus, 70 Hz for 2 min, repeated twice, centrifuged for 10 min at 13000 g (4 °C), and transfered supernatant into a new centrifuge tube. Samples were blow-dried by vacuum concentration. Chromatographic separation was carried out in the Shimadzu LC-30A system equipped with ACQUITY UPLC® HSS T3 (150 × 2.1 mm, 1.8 μm, Waters) column, with a column temperature of 40 °C. Gradient elution of the analytes was carried out with solvent A containing 0.1% formic acid in water and solvent B containing acetonitrile, at a flow rate of 0.3 mL/min. After equilibration, 5 μL of sample was injected into LC column, followed by an increasing linear gradient of solvent B (v/v): 0~0.5 min, 2% B; 0.5~9 min, 2%~ 50% B; 9~12 min, 50%~ 98% B; 12~13 min, 98% B; 13~14 min, 98%~ 2% B; 14~15 min, 2%.

Mass spectrometry (MS) analysis was executed in an electrospray ionization mode by using AB SCIEX TripleTOF™ 5600 System. The optimization of the operating parameters were achieved as follows: spray voltage, 5500 V (positive), 4500 V (negative); nebulizer gas (NEB), 50 psi; auxiliary gas (AUX), 50 psi; curtain gas (CUR), 35 psi; source temperature, 500 °C. Full-scan MS analysis was performed over the mass range of m/z 100–1500, with a collision energy of 45 eV.

Metabolites were characterized by comparisons with reference standards or MS/MS fragment information obtained from the Human Metabolome Database (HMDB) (http://www.hmdb.ca), the Metlin Database (http://metlin.scripps.edu), the massbank Database (http://www.massbank.jp/), the LipidMaps Database (http://www.lipidmaps.org) or the mzclound Database (https://www.mzcloud.org). We used IDA (Information Dependant Acquistion) and selected the signal intensity of the first 8 ions in the parent ion for secondary fragmentation (Additional file 8: Figure S1).

UPLC-MS (high resolution ultra-performance liquid chromatography-mass spectrometry) determination of amino acids

An equimolar standard mixture of all 20 amino acids(L-glycine, L-sarcosine, L-alanine, L-valine, L-proline, L-threonine, L-isoleucine, L-leucine, L-ornithine, L-methionine, L-histidine, L-phenylalanine, L-arginine, L-tyrosine, L-aspartic acid, L-tryptophan, 4-aminobutyric acid, L-serine, L-lysine, L-glutamic acid) was prepared, the final concentration was 0.2 μg/mL, 0.5 μg/mL, 1 μg/mL, 2 μg/mL, 5 μg/mL, 10 μg/mL, 20 μg/mL and 50 μg/mL.

100 mg of bacteria pellets was ground into fine powder in liquid nitrogen, amino acids were extracted with 1 mL HCl overnight. The tubes were centrifuged at 12000 rpm for 5 min to collecte the supernatant. 100 μL of isotope-labelled amino acids (Alanine -d4) internal standard was then added to the tube and blended, and drying with a moderate nitrogen gas stream. For derivatisation, 60 μL of derivatisation reagent [hydrochloric acid/n-butyl alcohol (1: 3, v/v)] was added into the mixture and reacted for 15 min at 65 °C. Then, the sample was separated and analysed by UPLC-MS.

The ACQUITY UPLC System equipped with a 1.7 μm C18 column (ACQUITY UPLC BEH, 2.1 × 100 mm, Waters) set at 40 °C was used for chromatographic separation. Gradient elution of the analytes was implemented with solvent A containing 0.1% formic acid and 0.1% heptafluorobutyric acid in acetonitrile, solvent B containing 0.1% formic acid in water, at a flow rate of 0.25 mL/min. Five microliter of sample was injected following equilibration. An increasing linear gradient of solvent A (v/v) was used as follows: 0~1.5 min, 5% A; 1.5~2 min, 5~20% A; 2~7 min, 20~30% A; 7~8.5 min, 30~98% A; 8.5~10.5 min, 98% A; 10.5~11 min, 98~5% A; 11~12.5 min, 5% A.

The ESI source was used in positive mode by multiple reaction monitoring (MRM) mode. The following conditions of detection were applied: ion source capillary voltage, 3200 V; cone voltage, 20 V; desolvation temperature, 380 °C.

Statistical analysis

All experiments were performed at least in biological triplicate and the results are presented as the mean ± standard deviation (SD). Values were considered to be statistically significant when P-value was < 0.05 and the statistical significance of the observed differences was assessed with one way analysis of variance (one-way ANOVA).

Abbreviations

ADP: 

Adenosine diphosphate

FDR: 

False discovery rate

GTP: 

Guanosine triphosphate

INH: 

Isoniazid

MDR: 

Multidrug resistant

MS: 

Mass spectrometry

Mtb: 

Mycobacterium tuberculosis

NAD: 

Adenine dinucleotide

OD: 

Optical density

PCR: 

Polymerase chain reaction

PFK: 

Phosphofructokinase

qRT-PCR: 

Quantitative real-time PCR

RIF: 

Rifampicin

SD: 

Standard deviation

TG: 

Triacylglycerol

TGS: 

Triacylglycerol synthase

ThDP: 

Thiamin diphosphate

ups: 

Universal stress proteins

VA : 

Vitamin A

VB1 : 

Vitamin B1

Vc: 

Vitamin C

VD : 

Vitamin D

Declarations

Acknowledgements

Not applicable.

Funding

The work was financially supported by National Key R&D Program of China (Grant No. 2017YFD0500906), the National Natural Science Foundation of China (Grant No.31873014 and 31772767) and National Key R&D Program of China (Grant No. 2017YFD0500304) for data interpretation and design of the study.

Availability of data and materials

The transcriptome analysis data are available in the GEO repository under accession number GSE114949 and the link is https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114949

Authors’ contributions

NNS performed the experiments and wrote the manuscript; ZLL performed the experiment including qRT-PCR; ZYC, LPC, YYC, GHD, ZL and HL did some transcriptome analysis;. SGL designed the experiment and corrected the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China

References

  1. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol. 2002;43(3):717–31.PubMedView ArticlePubMed CentralGoogle Scholar
  2. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med. 2003;198(5):693–704.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Fisher MA, Plikaytis BB, Shinnick TM. Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J Bacteriol. 2002;184(14):4025–32.PubMedPubMed CentralView ArticleGoogle Scholar
  4. Li XJ, Wu J, Han J, Hu YF, Mi KX. Distinct responses of Mycobacterium smegmatis to exposure to low and high levels of hydrogen peroxide. PLoS One. 2015;10(7).PubMedPubMed CentralView ArticleGoogle Scholar
  5. Sikri K, Batra SD, Nandi M, Kumari P, Taneja NK, Tyagi JS. The pleiotropic transcriptional response of Mycobacterium tuberculosis to vitamin C is robust and overlaps with the bacterial response to multiple intracellular stresses. Microbiol-Sgm. 2015;161:739–53.View ArticleGoogle Scholar
  6. Cappelli G, Volpe E, Grassi M, Liseo B, Colizzi V, Mariani F. Profiling of Mycobacterium tuberculosis gene expression during human macrophage infection: upregulation of the alternative sigma factor G, a group of transcriptional regulators, and proteins with unknown function. Res Microbiol. 2006;157(5):445–55.PubMedView ArticlePubMed CentralGoogle Scholar
  7. Rachman H, Strong M, Schaible U, Schuchhardt J, Hagens K, Mollenkopf H, Eisenberg D, Kaufmann SHE. Mycobacterium tuberculosis gene expression profiling within the context of protein networks. Microbes Infect. 2006;8(3):747–57.PubMedView ArticlePubMed CentralGoogle Scholar
  8. Tailleux L, Waddell SJ, Pelizzola M, Mortellaro A, Withers M, Tanne A, Castagnoli PR, Gicquel B, Stoker NG, Butcher PD, et al. Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS One. 2008;3(1).PubMedPubMed CentralView ArticleGoogle Scholar
  9. Warner DF. Mycobacterium tuberculosis Metabolism. Cold Spring Harbor perspectives in medicine. 2015;5(4).Google Scholar
  10. Ehrt S, Rhee K. Mycobacterium tuberculosis metabolism and host interaction: mysteries and paradoxes. Curr Top Microbiol Immunol. 2013;374:163–88.PubMedPubMed CentralGoogle Scholar
  11. Bi J, Wang H, Xie J. Comparative genomics of NAD(P) biosynthesis and novel antibiotic drug targets. J Cell Physiol. 2011;226(2):331–40.PubMedView ArticlePubMed CentralGoogle Scholar
  12. Salaemae W, Azhar A, Booker GW, Polyak SW. Biotin biosynthesis in Mycobacterium tuberculosis: physiology, biochemistry and molecular intervention. Protein & cell. 2011;2(9):691–5.View ArticleGoogle Scholar
  13. Hatzios SK, Bertozzi CR. The regulation of sulfur metabolism in Mycobacterium tuberculosis. PLoS Pathog. 2011;7(7):e1002036.PubMedPubMed CentralView ArticleGoogle Scholar
  14. Amon J, Titgemeyer F, Burkovski A. A genomic view on nitrogen metabolism and nitrogen control in mycobacteria. J Mol Microbiol Biotechnol. 2009;17(1):20–9.PubMedView ArticlePubMed CentralGoogle Scholar
  15. Shin JH, Yang JY, Jeon BY, Yoon YJ, Cho SN, Kang YH, Ryu DH, Hwang GS. H-1 NMR-based Metabolomic profiling in mice infected with Mycobacterium tuberculosis. J Proteome Res. 2011;10(5):2238–47.PubMedView ArticlePubMed CentralGoogle Scholar
  16. Somashekar BS, Amin AG, Tripathi P, MacKinnon N, Rithner CD, Shanley CA, Basaraba R, Henao-Tamayo M, Kato-Maeda M, Ramamoorthy A, et al. Metabolomic signatures in Guinea pigs infected with epidemic-associated W-Beijing strains of Mycobacterium tuberculosis. J Proteome Res. 2012;11(10):4873–84.PubMedView ArticlePubMed CentralGoogle Scholar
  17. Settembre E, Begley TP, Ealick SE. Structural biology of enzymes of the thiamin biosynthesis pathway. Curr Opin Struc Biol. 2003;13(6):739–47.View ArticleGoogle Scholar
  18. Begley TP, Downs DM, Ealick SE, McLafferty FW, Van Loon APGM, Taylor S, Campobasso N, Chiu HJ, Kinsland C, Reddick JJ, et al. Thiamin biosynthesis in prokaryotes. Arch Microbiol. 1999;171(5):293–300.PubMedView ArticlePubMed CentralGoogle Scholar
  19. Pohl M, Sprenger GA, Muller M. A new perspective on thiamine catalysis. Curr Opin Biotech. 2004;15(4):335–42.PubMedView ArticlePubMed CentralGoogle Scholar
  20. Hosomi K, Kunisawa J. The specific roles of vitamins in the regulation of Immunosurveillance and maintenance of immunologic homeostasis in the gut. Immune network. 2017;17(1):13–9.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Manzetti S, Zhang J, van der Spoel D. Thiamin function, metabolism, uptake, and transport. Biochemistry. 2014;53(5):821–35.PubMedView ArticlePubMed CentralGoogle Scholar
  22. Gibson GE, Blass JP. Thiamine-dependent processes and treatment strategies in neurodegeneration. Antioxid Redox Signal. 2007;9(10):1605–19.PubMedView ArticlePubMed CentralGoogle Scholar
  23. Butterworth RF, Besnard AM. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease. Metab Brain Dis. 1990;5(4):179–84.PubMedView ArticlePubMed CentralGoogle Scholar
  24. Huang HM, Chen HL, Gibson GE. Thiamine and oxidants interact to modify cellular calcium stores. Neurochem Res. 2010;35(12):2107–16.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Gangolf M, Wins P, Thiry M, El Moualij B, Bettendorff L. Thiamine triphosphate synthesis in rat brain occurs in mitochondria and is coupled to the respiratory chain. J Biol Chem. 2010;285(1):583–94.PubMedView ArticlePubMed CentralGoogle Scholar
  26. Syal K, Chakraborty S, Bhattacharyya R, Banerjee D. Combined inhalation and oral supplementation of vitamin a and vitamin D: a possible prevention and therapy for tuberculosis. Med Hypotheses. 2015;84(3):199–203.PubMedView ArticlePubMed CentralGoogle Scholar
  27. Dini C, Bianchi A. The potential role of vitamin D for prevention and treatment of tuberculosis and infectious diseases. Ann I Super Sanita. 2012;48(3):319–27.View ArticleGoogle Scholar
  28. Vilcheze C, Hartman T, Weinrick B, Jacobs WR. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nat Commun. 2013;4.Google Scholar
  29. Riaz H, Riaz I, Abir T, Badshah M, Milton A. Vitamin D as a supplementary agent in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis of randomized controlled trials. Eur Respir J. 2013:42.Google Scholar
  30. He W, Hu S, Du X, Wen Q, Zhong XP, Zhou X, Zhou C, Xiong W, Gao Y, Zhang S, et al. Vitamin B5 reduces bacterial growth via regulating innate immunity and adaptive immunity in mice infected with Mycobacterium tuberculosis. Front Immunol. 2018;9:365.PubMedPubMed CentralView ArticleGoogle Scholar
  31. Song N, Cui Y, Li Z, Chen L, Liu S. New targets and cofactors for the transcription factor LrpA from Mycobacterium tuberculosis. DNA Cell Biol. 2016;35(4):167–76.PubMedView ArticleGoogle Scholar
  32. Luong K, Nguyen LT. Impact of vitamin D in the treatment of tuberculosis. Am J Med Sci. 2011;341(6):493–8.PubMedView ArticleGoogle Scholar
  33. Huang QQ, Abdalla AE, Xie JP. Phylogenomics of Mycobacterium nitrate reductase operon. Curr Microbiol. 2015;71(1):121–8.PubMedView ArticleGoogle Scholar
  34. Weber I, Fritz C, Ruttkowski S, Kreft A, Bange FC. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol Microbiol. 2000;35(5):1017–25.PubMedView ArticleGoogle Scholar
  35. Gao CH, Yang M, He ZG. Characterization of a novel ArsR-like regulator encoded by Rv2034 in Mycobacterium tuberculosis. PLoS One. 2012;7(4):e36255.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Commandeur S, van Meijgaarden KE, Prins C, Pichugin AV, Dijkman K, van den Eeden SJF, Friggen AH, Franken KLMC, Dolganov G, Kramnik I, et al. An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. J Immunol. 2013;190(4):1659–71.PubMedView ArticleGoogle Scholar
  37. Commandeur S, Coppola M, Dijkman K, Friggen AH, van Meijgaarden KE, Van den Eeden SJF, Wilson L, Van der Ploeg-van Schip JJ, Franken KLMC, Geluk A, et al. Clonal analysis of the T-cell response to in vivo expressed Mycobacterium tuberculosis protein Rv2034, using a CD154 expression based T-cell cloning method. PLoS One. 2014;9(6).PubMedPubMed CentralView ArticleGoogle Scholar
  38. Kendall SL, Withers M, Soffair CN, Moreland NJ, Gurcha S, Sidders B, Frita R, ten Bokum A, Besra GS, Lott JS, et al. A highly conserved transcriptional repressor controls a large regulon involved in lipid degradation in Mycobacterium smegmatis and Mycobacterium tuberculosis. Mol Microbiol. 2007;65(3):684–99.PubMedPubMed CentralView ArticleGoogle Scholar
  39. Gomez RL, Jose L, Ramachandran R, Raghunandanan S, Muralikrishnan B, Johnson JB, Sivakumar KC, Mundayoor S, Kumar RA. The multiple stress responsive transcriptional regulator Rv3334 of Mycobacterium tuberculosis is an autorepressor and a positive regulator of kstR. FEBS J. 2016;283(16):3056–71.PubMedView ArticleGoogle Scholar
  40. Galagan JE, Minch K, Peterson M, Lyubetskaya A, Azizi E, Sweet L, Gomes A, Rustad T, Dolganov G, Glotova I, et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature. 2013;499(7457):178–83.PubMedPubMed CentralView ArticleGoogle Scholar
  41. Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, Boom WH, Dockrell HM, Franken KLMC, Friggen AH, Hill PC, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol. 2009;16(8):1203–12.PubMedPubMed CentralView ArticleGoogle Scholar
  42. Dasgupta N, Kapur V, Singh KK, Das TK, Sachdeva S, Jyothisri K, Tyagi JS. Characterization of a two component system, devR-devS, of Mycobacterium tuberculosis. Tubercle Lung Dis. 2000;80(3):141–59.View ArticleGoogle Scholar
  43. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK, Sherman DR. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol. 2003;48(3):833–43.PubMedPubMed CentralView ArticleGoogle Scholar
  44. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med. 2003;198(5):705–13.PubMedPubMed CentralView ArticleGoogle Scholar
  45. Shiloh MU, Manzanillo P, Cox JS. Mycobacterium tuberculosis senses host-derived carbon monoxide during macrophage infection. Cell Host Microbe. 2008;3(5):323–30.PubMedPubMed CentralView ArticleGoogle Scholar
  46. Taneja NK, Dhingra S, Mittal A, Naresh M, Tyagi JS. Mycobacterium tuberculosis transcriptional adaptation, growth arrest and dormancy phenotype development is triggered by vitamin C. PLoS One. 2010;5(5).PubMedPubMed CentralView ArticleGoogle Scholar
  47. Chauhan S, Sharma D, Singh A, Surolia A, Tyagi JS. Comprehensive insights into Mycobacterium tuberculosis DevR (DosR) regulon activation switch. Nucleic Acids Res. 2011;39(17):7400–14.PubMedPubMed CentralView ArticleGoogle Scholar
  48. Leistikow RL, Morton RA, Bartek IL, Frimpong I, Wagner K, Voskuil MI. The Mycobacterium tuberculosis DosR regulon assists in metabolic homeostasis and enables rapid recovery from nonrespiring dormancy. J Bacteriol. 2010;192(6):1662–70.PubMedView ArticleGoogle Scholar
  49. Stallings CL, Stephanou NC, Chu L, Hochschild A, Nickels BE, Glickman MS. CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence. Cell. 2009;138(1):146–59.PubMedPubMed CentralView ArticleGoogle Scholar
  50. Singh A, Crossman DK, Mai D, Guidry L, Voskuil MI, Renfrow MB, Steyn AJC. Mycobacterium tuberculosis WhiB3 maintains redox homeostasis by regulating virulence lipid anabolism to modulate macrophage response. PLoS Pathog. 2009;5(8).PubMedPubMed CentralView ArticleGoogle Scholar
  51. Geiman DE, Raghunand TR, Agarwal N, Bishai WR. Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes. Antimicrob Agents Ch. 2006;50(8):2836–41.View ArticleGoogle Scholar
  52. Mishra A, Sarkar D. Qualitative and quantitative proteomic analysis of vitamin C induced changes in Mycobacterium smegmatis. Front Microbiol. 2015;6.Google Scholar
  53. Larsson C, Luna B, Ammerman NC, Maiga M, Agarwal N, Bishai WR. Gene expression of Mycobacterium tuberculosis putative transcription factors whiB1-7 in redox environments. PLoS One. 2012;7(7).PubMedPubMed CentralView ArticleGoogle Scholar
  54. Chen ZK, Hu YB, Cumming BM, Lu P, Feng LP, Deng JY, Steyn AJC, Chen SY. Mycobacterial WhiB6 differentially regulates ESX-1 and the dos regulon to modulate granuloma formation and virulence in zebrafish. Cell Rep. 2016;16(9):2512–24.PubMedView ArticleGoogle Scholar
  55. Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell. 2009;136(1):37–49.PubMedPubMed CentralView ArticleGoogle Scholar
  56. Ang MLT, Rahim SZZ, Shui GH, Dianiskova P, Madacki J, Lin WW, Koh VHQ, Gomez JMM, Sudarkodi S, Bendt A et al: An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence In Vivo, which correlate with altered mycolic acid composition (vol 82, pg 1850, 2014). Infect Immun 2015, 83(2):846Google Scholar
  57. Bolla JR, Do SV, Long F, Dai L, Su CC, Lei HT, Chen X, Gerkey JE, Murphy DC, Rajashankar KR, et al. Structural and functional analysis of the transcriptional regulator Rv3066 of Mycobacterium tuberculosis. Nucleic Acids Res. 2012;40(18):9340–55.PubMedPubMed CentralView ArticleGoogle Scholar
  58. De Rossi E, Branzoni M, Cantoni R, Milano A, Riccardi G, Ciferri O. mmr, a Mycobacterium tuberculosis gene conferring resistance to small cationic dyes and inhibitors. J Bacteriol. 1998;180(22):6068–71.PubMedPubMed CentralGoogle Scholar
  59. Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial Thioridazine. PLoS One. 2010;5(4).PubMedPubMed CentralView ArticleGoogle Scholar
  60. Gong CL, Martins A, Bongiorno P, Glickman M, Shuman S. Biochemical and genetic analysis of the four DNA ligases of mycobacteria. J Biol Chem. 2004;279(20):20594–606.PubMedView ArticleGoogle Scholar
  61. Kumar A, Majid M, Kunisch R, Rani PS, Qureshi IA, Lewin A, Hasnain SE, Ahmed N. Mycobacterium tuberculosis DosR regulon gene Rv0079 encodes a putative, 'Dormancy associated translation inhibitor (DATIN). PLoS One. 2012;7(6).PubMedPubMed CentralView ArticleGoogle Scholar
  62. Mishra S. Function prediction of Rv0079, a hypothetical Mycobacterium tuberculosis DosR regulon protein. J Biomol Struct Dyn. 2009;27(3):283–91.PubMedView ArticleGoogle Scholar
  63. Kumar A, Lewin A, Rani PS, Qureshi IA, Devi S, Majid M, Kamal E, Marek S, Hasnain SE, Ahmed N. Dormancy associated translation inhibitor (DATIN/Rv0079) of Mycobacterium tuberculosis interacts with TLR2 and induces proinflammatory cytokine expression. Cytokine. 2013;64(1):258–64.View ArticleGoogle Scholar
  64. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet. 1988;22:631–77.PubMedView ArticleGoogle Scholar
  65. Mayhew M, da Silva AC, Martin J, Erdjument-Bromage H, Tempst P, Hartl FU. Protein folding in the central cavity of the GroEL-GroES chaperonin complex. Nature. 1996;379(6564):420–6.PubMedView ArticleGoogle Scholar
  66. Goyal K, Qamra R, Mande SC. Multiple gene duplication and rapid evolution in the groEL gene: functional implications. J Mol Evol. 2006;63(6):781–7.PubMedView ArticleGoogle Scholar
  67. Smollett KL, Smith KM, Kahramanoglou C, Arnvig KB, Buxton RS, Davis EO. Global analysis of the regulon of the transcriptional repressor LexA, a key component of SOS response in Mycobacterium tuberculosis. J Biol Chem. 2012;287(26):22004–14.PubMedPubMed CentralView ArticleGoogle Scholar
  68. Miner MD, Chang JC, Pandey AK, Sassetti CM, Sherman DR. Role of cholesterol in Mycobacterium tuberculosis infection. Indian J Exp Biol. 2009;47(6):407–11.PubMedGoogle Scholar
  69. Nesbitt NM, Yang XX, Fontan P, Kolesnikova I, Smith I, Sampson NS, Dubnau E. A Thiolase of Mycobacterium tuberculosis is required for virulence and production of androstenedione and Androstadienedione from cholesterol. Infect Immun. 2010;78(1):275–82.PubMedView ArticleGoogle Scholar
  70. Carroll P, Parish T. Deletion of cyp125 confers increased sensitivity to azoles in Mycobacterium tuberculosis. PLoS One. 2015;10(7).PubMedPubMed CentralView ArticleGoogle Scholar
  71. Sirakova TD, Dubey VS, Deb C, Daniel J, Korotkova TA, Abomoelak B, Kolattukudy PE. Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress. Microbiol-Sgm. 2006;152:2717–25.View ArticleGoogle Scholar
  72. Phong WY, Lin WW, Rao SPS, Dick T, Alonso S, Pethe K. Characterization of phosphofructokinase activity in Mycobacterium tuberculosis reveals that a functional glycolytic carbon flow is necessary to limit the accumulation of toxic metabolic intermediates under hypoxia. PLoS One. 2013;8(2).PubMedPubMed CentralView ArticleGoogle Scholar
  73. Wagner D, Maser J, Lai B, Cai ZH, Barry CE, Bentrup KHZ, Russell DG, Bermudez LE. Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates pathogen-induced microenvironments within the host cell's endosomal system. J Immunol. 2005;174(3):1491–500.PubMedView ArticlePubMed CentralGoogle Scholar
  74. Wardman P, Candeias LP. Fenton chemistry: an introduction. Radiat Res. 1996;145(5):523–31.PubMedView ArticlePubMed CentralGoogle Scholar
  75. Macomber L, Imlay JA. The iron-sulfur clusters of dehydratases are primary intracellular targets of copper toxicity. P Natl Acad Sci USA. 2009;106(20):8344–9.View ArticleGoogle Scholar
  76. Ramirez-Cardenas L, Costa NMB, Reis FP. Copper-iron metabolism interaction in rats. Nutr Res. 2005;25(1):79–92.View ArticleGoogle Scholar
  77. Marcus SA, Sidiropoulos SW, Steinberg H, Talaat AM. CsoR is essential for maintaining copper homeostasis in Mycobacterium tuberculosis. PLoS One. 2016;11(3).PubMedPubMed CentralView ArticleGoogle Scholar
  78. Liu T, Ramesh A, Ma Z, Ward SK, Zhang LM, George GN, Talaat AM, Sacchettini JC, Giedroc DP. CsoR is a novel Mycobacterium tuberculosis copper-sensing transcriptional regulator. Nat Chem Biol. 2007;3(1):60–8.PubMedView ArticleGoogle Scholar
  79. Ward SK, Abomoelak B, Hoye EA, Steinberg H, Talaat AM. CtpV: a putative copper exporter required for full virulence of Mycobacterium tuberculosis. Mol Microbiol. 2010;77(5):1096–110.PubMedPubMed CentralView ArticleGoogle Scholar
  80. Braibant M, Gilot P, Content J. The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol Rev. 2000;24(4):449–67.PubMedView ArticlePubMed CentralGoogle Scholar
  81. Green RM, Seth A, Connell ND. A peptide permease mutant of Mycobacterium bovis BCG resistant to the toxic peptides glutathione and S-nitrosoglutathione. Infect Immun. 2000;68(2):429–36.PubMedPubMed CentralView ArticleGoogle Scholar
  82. Dasgupta A, Sureka K, Mitra D, Saha B, Sanyal S, Das AK, Chakrabarti P, Jackson M, Gicquel B, Kundu M, et al. An oligopeptide transporter of Mycobacterium tuberculosis regulates cytokine release and apoptosis of infected macrophages. PLoS One. 2010;5(8).PubMedPubMed CentralView ArticleGoogle Scholar
  83. Flores-Valdez MA, Morris RP, Laval F, Daffe M, Schoolnik GK. Mycobacterium tuberculosis modulates its cell surface via an oligopeptide permease (Opp) transport system. FASEB J. 2009;23(12):4091–104.PubMedPubMed CentralView ArticleGoogle Scholar
  84. Griffin JE, Gawronski JD, DeJesus MA, Ioerger TR, Akerley BJ, Sassetti CM. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog. 2011;7(9).PubMedPubMed CentralView ArticleGoogle Scholar
  85. Fullam E, Prokes I, Futterer K, Besra GS. Structural and functional analysis of the solute-binding protein UspC from Mycobacterium tuberculosis that is specific for amino sugars. Open Biol. 2016;6(6).PubMedPubMed CentralView ArticleGoogle Scholar
  86. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003;16(3):463.PubMedPubMed CentralView ArticleGoogle Scholar
  87. Gande R, Gibson KJC, Brown AK, Krumbach K, Dover LG, Sahm H, Shioyama S, Oikawa T, Besra GS, Eggeling L. Acyl-CoA carboxylases (accD2 and accD3), together with a unique polyketide synthase (cg-pks), are key to mycolic acid biosynthesis in corynebacterianeae such as Corynebacterium glutamicum and Mycobacterium tuberculosis. J Biol Chem. 2004;279(43):44847–57.PubMedView ArticlePubMed CentralGoogle Scholar
  88. Singhal N, Sharma P, Kumar M, Joshi B, Bisht D. Analysis of intracellular expressed proteins of Mycobacterium tuberculosis clinical isolates. Proteome Sci. 2012;10.PubMedPubMed CentralView ArticleGoogle Scholar
  89. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence (vol 393, pg 537, 1998). Nature. 1998;396(6707):190–8.View ArticleGoogle Scholar
  90. Ramakrishnan L, Federspiel NA, Falkow S. Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science. 2000;288(5470):1436–9.PubMedView ArticlePubMed CentralGoogle Scholar
  91. Sampson SL, Lukey P, Warren RM, van Helden PD, Richardson M, Everett MJ. Expression, characterization and subcellular localization of the Mycobacterium tuberculosis PPE gene Rv1917c. Tuberculosis. 2001;81(5–6):305–17.PubMedView ArticlePubMed CentralGoogle Scholar
  92. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, Allen RD, Gluck SL, Heuser J, Russell DG. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 1994;263(5147):678–81.PubMedView ArticlePubMed CentralGoogle Scholar
  93. Li YJ, Miltner E, Wu M, Petrofsky M, Bermudez LE. A Mycobacterium avium PPE gene is associated with the ability of the bacterium to grow in macrophages and virulence in mice. Cell Microbiol. 2005;7(4):539–48.PubMedView ArticlePubMed CentralGoogle Scholar
  94. Zhang HM, Wang JL, Lei JQ, Zhang M, Yang YP, Chen Y, Wang HH. PPE protein (Rv3425) from DNA segment RD11 of Mycobacterium tuberculosis: a potential B-cell antigen used for serological diagnosis to distinguish vaccinated controls from tuberculosis patients. Clin Microbiol Infec. 2007;13(2):139–45.View ArticleGoogle Scholar
  95. Xu Y, Yang E, Wang J, Li R, Li G, Liu G, Song N, Huang Q, Kong C, Wang H. Prime-boost bacillus Calmette-Guerin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice. Immunology. 2014;143(2):277–86.PubMedPubMed CentralView ArticleGoogle Scholar
  96. Chevrier D, Casademont I, Guesdon JL. Cloning of a gene from Mycobacterium tuberculosis coding for a hypothetical 27 kDa protein and its use for the specific PCR identification of these mycobacteria. Mol Cell Probes. 2000;14(4):241–8.PubMedView ArticlePubMed CentralGoogle Scholar
  97. Le Moigne V, Robreau G, Borot C, Guesdon JL, Mahana W. Expression, immunochemical characterization and localization of the Mycobacterium tuberculosis protein p27. Tuberculosis. 2005;85(4):213–9.PubMedView ArticlePubMed CentralGoogle Scholar
  98. Le Moigne V, Le Moigne D, Mahana W. Antibody response to Mycobacterium tuberculosis p27-PPE36 antigen in sera of pulmonary tuberculosis patients. Tuberculosis. 2013;93(2):189–91.PubMedView ArticlePubMed CentralGoogle Scholar
  99. Bretl DJ, He H, Demetriadou C, White MJ, Penoske RM, Salzman NH, Zahrt TC. MprA and DosR coregulate a Mycobacterium tuberculosis virulence operon encoding Rv1813c and Rv1812c. Infect Immun. 2012;80(9):3018–33.PubMedPubMed CentralView ArticleGoogle Scholar
  100. Hingley-Wilson SM, Lougheed KEA, Ferguson K, Leiva S, Williams HD. Individual Mycobacterium tuberculosis universal stress protein homologues are dispensable in vitro. Tuberculosis. 2010;90(4):236–44.PubMedView ArticlePubMed CentralGoogle Scholar
  101. Pedley AM, Benkovic SJ. A new view into the regulation of purine metabolism: the Purinosome. Trends Biochem Sci. 2017;42(2):141–54.PubMedView ArticlePubMed CentralGoogle Scholar
  102. Lu'o'ng KV, Nguyen LT. The role of thiamine in cancer: possible genetic and cellular signaling mechanisms. Cancer genomics proteomics. 2013;10(4):169–85.PubMedPubMed CentralGoogle Scholar
  103. Khanh VQL, Lan THN. Thiamine and Parkinson's disease. J Neurol Sci. 2012;316(1–2):1–8.Google Scholar
  104. Lu'o'ng KVQ, Nguyen LTH. The role of thiamine in HIV infection. Int J Infect Dis. 2013;17(4):E221–7.View ArticleGoogle Scholar
  105. Ren WK, Rajendran R, Zhao YY, Tan B, Wu GY, Bazer FW, Zhu GQ, Peng YY, Huang XS, Deng JP, et al. Amino acids as mediators of metabolic cross talk between host and pathogen. Front Immunol. 2018;9.Google Scholar
  106. Gouzy A, Larrouy-Maumus G, Wu TD, Peixoto A, Levillain F, Lugo-Villarino G, Guerquin-Kern JL, de Carvalho LPS, Poquet Y, Neyrolles O. Mycobacterium tuberculosis nitrogen assimilation and host colonization require aspartate. Nat Chem Biol. 2013;9(11):674.PubMedView ArticlePubMed CentralGoogle Scholar
  107. Gouzy A, Poquet Y, Neyrolles O. A central role for aspartate in Mycobacterium tuberculosis physiology and virulence. Front Cell Infect Mi. 2013;3.Google Scholar
  108. Gouzy A, Larrouy-Maumus G, Bottai D, Levillain F, Dumas A, Wallach JB, Caire-Brandli I, de Chastellier C, Wu TD, Poincloux R, et al. Mycobacterium tuberculosis exploits asparagine to assimilate nitrogen and resist acid stress during infection. PLoS Pathog. 2014;10(2).PubMedPubMed CentralView ArticleGoogle Scholar
  109. Lyon RH, Hall WH, Costas-Martinez C. Utilization of amino acids during growth of Mycobacterium tuberculosis in rotary cultures. Infect Immun. 1970;1(6):513–20.PubMedPubMed CentralGoogle Scholar
  110. Reitzer L. Biosynthesis of glutamate, aspartate, asparagine, L-alanine, and D-alanine. EcoSal Plus. 2004;1(1).Google Scholar
  111. Chen JM, Alexander DC, Behr MA, Liu J. Mycobacterium bovis BCG vaccines exhibit defects in alanine and serine catabolism. Infect Immun. 2003;71(2):708–16.PubMedPubMed CentralView ArticleGoogle Scholar
  112. Wu G. Amino acids: metabolism, functions, and nutrition. Amino Acids. 2009;37(1):1–17.PubMedView ArticlePubMed CentralGoogle Scholar
  113. Ren W, Yin J, Duan J, Liu G, Tan B, Yang G, Wu G, Bazer FW, Peng Y, Yin Y. mTORC1 signaling and IL-17 expression: defining pathways and possible therapeutic targets. Eur J Immunol. 2016;46(2):291–9.PubMedView ArticlePubMed CentralGoogle Scholar
  114. Ren W, Liu G, Chen S, Yin J, Wang J, Tan B, Wu G, Bazer FW, Peng Y, Li T, et al. Melatonin signaling in T cells: functions and applications. J Pineal Res. 2017;62(3).View ArticleGoogle Scholar
  115. Ren W, Liu G, Yin J, Tan B, Wu G, Bazer FW, Peng Y, Yin Y. Amino-acid transporters in T-cell activation and differentiation. Cell Death Dis. 2017;8(5):e2757.PubMedPubMed CentralView ArticleGoogle Scholar
  116. Fang Y, French J, Zhao H, Benkovic S. G-protein-coupled receptor regulation of de novo purine biosynthesis: a novel druggable mechanism. Biotechnol Genet Eng Rev. 2013;29:31–48.PubMedView ArticlePubMed CentralGoogle Scholar
  117. Schmidt H, Siems WG, Grune T, Grauel EL. Concentration of purine compounds in the cerebrospinal-fluid of infants suffering from Sepsis, convulsions and hydrocephalus. J Perinat Med. 1995;23(3):167–74.PubMedView ArticlePubMed CentralGoogle Scholar
  118. Jabs CM, Neglen P, Eklof B. Breakdown of adenine-nucleotides, formation of oxygen-free radicals, and early markers of cellular injury in Endotoxic-shock. Eur J Surg. 1995;161(3):147–55.PubMedPubMed CentralGoogle Scholar
  119. Jin X, Shepherd RK, Duling BR, Linden J. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest. 1997;100(11):2849–57.PubMedPubMed CentralView ArticleGoogle Scholar
  120. Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC, Koprowski H. The treatment of multiple sclerosis with inosine. J Altern Complement Med. 2009;15(6):619–25.PubMedPubMed CentralView ArticleGoogle Scholar
  121. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105–11.PubMedPubMed CentralView ArticleGoogle Scholar
  122. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511–5.PubMedPubMed CentralView ArticleGoogle Scholar
  123. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57(1):289–300.Google Scholar
  124. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29(4):1165–88.View ArticleGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement

BMC Microbiology

ISSN: 1471-2180

Contact us